V.S. KRASNOV¹, Yu.A. RUDNEVA¹, V.D. NAZAROV¹, A.V. VLADYKINA¹, S.V. LAPIN¹, L.G. ZASLAVSKII^{1, 2}, N.A. TOTOLYAN¹

 ¹Academician I.P. Pavlov First St. Petersburg State Medical University, Saint-Petersburg

²Leningrad Regional Clinic Hospital, Saint-Petersburg

 Contact details:

Krasnov V.S. — PhD (medicine), Associate Professor of the Neurology Department

Address: 6–8 Lva Tolstogo St., Russian Federation, Saint-Petersburg, 197022, tel.: +7 (812) 338-71-83, e-mail: krasnov_volod@mail.ru

The purpose — to systematize the modern concepts of diagnosis and treatment for myelin oligodendrocyte glycoprotein (MOG)-IgG-associated disorder.

Material and methods. A search for modern publications was carried out using electronic scientific databases PubMed, Science Direct Open Access, Free Medical Journals. Keywords such as MOG-IgG-associated disorder, MOG-encephalomyelitis, MОG-antibody-associated disease were used for search of literature. Modern publications on the nomenclature, pathogenesis, diagnosis and treatment of MOG-IgG-associated disorder as well as scientific works devoted to the history of the study of this problem published in the period from 1987 to 2020 were selected and analyzed.

Results. The diagnosis of MOG-IgG-associated disease is based on a combination of clinical, neuroimaging and laboratory assessments with exclusion of alternative conditions. There are many challenges in pathogenesis and nomenclature. Diagnostic criteria were published in 2018. Presence of certain indications is advisable for conducting a blood serum test for MOG-IgG according to the international recommendations. The key diagnostic test proposed is antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) detected in serum with cell-based assays (indirect fluorescence test or fluorescence-activating cell sorting) with strictly employing conformationally intact full-length human MOG as target antigen. There are no generally accepted standards of therapy.The approaches to therapy recommended by various expert working groups are based on the protocols for the management of patients with AQP4-IgG-positive forms of neuromyelitisoptica spectrum disorder.

Conclusion. MOG-IgG-associated disorder is a recently proposed group of inflammatory demyelinating syndromes which are different from other demyelinating diseases. Currently it is advisable to use the diagnostic criteria published in 2018. Current knowledge allowed formulating recommendations for laboratory diagnostics which have limited availability in everyday practice. Treatment issues need to be systematized after achieving eхpert consensus.

Key words: antibodies to myelin oligodendrocyte glycoprotein, MOG-IgG-associated disorder, diagnostic criteria.

REFERENCES

1. Tea F., Lopez J.A., Ramanathan S. et al. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathol commun., 2019, vol. 7, p. 145.
2. Jurynczyk M., Messina S., Woodhallet M.R. et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, vol. 140 (12), pp. 3128–3138.
3. Wynford-Thomas R., Jacob A., Tomassini V. Neurological update: MOG antibody disease. J Neurol, 2019, vol. 266, pp. 1280–1286.
4. Jarius S., Paul F., Aktas O. et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroin flammation, 2018,vol. 15, p. 134.
5. López-Chiriboga A.S., Majed M., Fryer J. et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders. JAMA Neurol, 2018, vol. 75 (11), pp. 1355–1363.
6. Juryńczyk M., Jacob A., Fujihara K., Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol, 2019, vol. 19 (3), pp. 187–195.
7. Xiao B.G., Linington C., Link H. Antibodies to myelinoligodendrocyteglycoprotein in cerebrospinal fluid frompatients with multiple sclerosis and controls. J Neuroimmunol, 1991, vol. 31, pp. 91–96.
8. Reindl M., Linington C., Brehm U. et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basicprotein in multiple sclerosis and other neurological diseases: acomparative study. Brain, 1999, vol. 122, pp. 2047–2056.
9. Adelmann M., Wood J., Benzel I. et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune en cephalomyelitis in the Lewis rat. J Neuroimmunol, 1995, vol. 63, pp. 17–27.
10. Berger T., Rubner P., Schautzer F. et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Eng J, 2003, vol. 349, pp. 139–145.
11. Papathanasiou A., Tanasescu R., Davis J. et al. MOG‐IgG‐associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. J Neurol, 2020, Vol. 267 (2), pp. 359–368.
12. Waters P. J., Komorowski L., Woodhall M. et al. MDA multicenter comparison of MOG-IgG cellbased-assays. Neurology, 2019, vol. 92, pp. 1–6.
13. Whittam D.H., Karthikeayan V., Gibbons E. et al. Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology, 2020,Published online.
14. Linington C., Mogan B.P., Scolding N.J. et al. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain, 1989, vol. 112 (4), pp. 895–911.
15. Mader S., Gredler V., Schanda K. et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitisoptica and related disorders. J Neuroin flammation, 2011, vol. 8, p. 184.
16. Schluesener H.J., Sobel R.A., Linington C., Weiner H.L. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol, 1987, vol. 139 (12), pp. 4016–4021.
17. Bernard C.C., Johns T.G., Slavin A. et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med (Berl), 1997, vol. 75 (2), pp. 77–88.
18. Peschl P., Bradl M., Höftberger R. et al. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Frontiers in immunology, 2017, vol. 8, p. 529.
19. Ramanathan S., Dale R.C., Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev, 2016, vol. 15 (4), pp. 307–324.
20. Höftberger R., GuoY., Flanagan E.P. et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol, 2020, vol. 139, pp. 875–892.
21. Flach A.C., Litke T., Strauss J. et al. Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proc Natl Acad Sci USA,2016, vol. 113 (12), p. 3323.
22. Kinzel S., Lehmann-Horn K., Torke S.et al. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol, 2016, vol. 132 (1), pp. 43–58.
23. Mariotto S., Ferrari S., Monaco S. et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol, 2017, vol. 264 (12), pp. 2420–2430.
24. Cobo-Calvo A., Ruiz A., Maillart E. et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology, 2018, vol. 90, pp. 1858–1869.
25. Deneve M., Biotti D., Patsouraet S. et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiology, 2019, vol. 46, pp. 312–318.
26. Reindl M., Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol, 2019, vol. 15, pp. 89–102.
27. Cellina M., Fetoni V., Ciocca M. et al. Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review. Neuroradiol J, 2018, vol. 31 (1), pp. 69–82.
28. Ramanathan S., Mohammad S., Tantsis E. et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry, 2018, vol. 89 (2), pp. 127–137.
29. Biotti D., Bonneville F., Tournaire E. et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol, 2017, vol. 264, pp. 2173–2175.
30. Hennes E.M., Baumann M., Lechner C., Rostásy K.MOG spectrum disorders and role of MOG-antibodies in clinical practice. Neuropediatrics, 2017, vol. 49 (1), pp. 3–11.
31. O’Connor K.C., McLaughlin K.A., De Jager P.L. et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med, 2007, vol. 13, pp. 211–217.
32. Water P., Woodhall M., O’Connor K.C. et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuro in flamm, 2015, vol. 2 (3), p. 89.
33. Jurynczyk M., Probert F., Yeo T. et al. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathol Commun, 2017, vol. 5 (1), p. 95.
34. Juryńczyk M., Tackley G., Kong Y. et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry, 2017, pp. 88 (2), pp. 132–136.
35. Jarius S., Ruprecht K., Kleiter I. et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroin flammation, 2016, vol. 13, p. 280.